Drugs / PF-06804103
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03284723 | Nov 2017 → Aug 2021 | breast neoplasm | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06804103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03284723 ↗ |
| Route | Intravenous | “received PF-06804103 0.15-5.0 mg/kg intravenously once/21 days (Q3W)” PMID 37420274 ↗ Oct 2023 |
| Target | ERBB2 | “PF-06804103 is an anti-HER2 antibody-drug conjugate with auristatin payload.” PMID 37420274 ↗ Oct 2023 |